669 related articles for article (PubMed ID: 18021759)
21. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
Ligresti A; Moriello AS; Starowicz K; Matias I; Pisanti S; De Petrocellis L; Laezza C; Portella G; Bifulco M; Di Marzo V
J Pharmacol Exp Ther; 2006 Sep; 318(3):1375-87. PubMed ID: 16728591
[TBL] [Abstract][Full Text] [Related]
22. Dose and behavioral context dependent inhibition of movement and basal ganglia neural activity by Delta-9-tetrahydrocannabinol during spontaneous and treadmill locomotion tasks in rats.
Shi LH; Luo F; Woodward DJ; Chang JY
Synapse; 2005 Jan; 55(1):1-16. PubMed ID: 15499609
[TBL] [Abstract][Full Text] [Related]
23. Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain.
Tripathi HL; Vocci FJ; Brase DA; Dewey WL
Alcohol Drug Res; 1987; 7(5-6):525-32. PubMed ID: 3620017
[TBL] [Abstract][Full Text] [Related]
24. Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol.
Beardsley PM; Scimeca JA; Martin BR
J Pharmacol Exp Ther; 1987 May; 241(2):521-6. PubMed ID: 3033218
[TBL] [Abstract][Full Text] [Related]
25. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
26. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol.
Buchweitz JP; Karmaus PW; Williams KJ; Harkema JR; Kaminski NE
J Leukoc Biol; 2008 Mar; 83(3):785-96. PubMed ID: 18073275
[TBL] [Abstract][Full Text] [Related]
27. Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption.
Stern CA; Gazarini L; Vanvossen AC; Zuardi AW; Galve-Roperh I; Guimaraes FS; Takahashi RN; Bertoglio LJ
Eur Neuropsychopharmacol; 2015 Jun; 25(6):958-65. PubMed ID: 25799920
[TBL] [Abstract][Full Text] [Related]
28. Delta 9-tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices.
Reichman M; Nen W; Hokin LE
Mol Pharmacol; 1988 Dec; 34(6):823-8. PubMed ID: 2849049
[TBL] [Abstract][Full Text] [Related]
29. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
[TBL] [Abstract][Full Text] [Related]
30. The influence of delta9-tetrahydrocannabinol, cannabinol and cannabidiol on tissue oxygen consumption.
Chiu P; Karler R; Craven C; Olsen DM; Turkanis SA
Res Commun Chem Pathol Pharmacol; 1975 Oct; 12(2):267-86. PubMed ID: 1197914
[TBL] [Abstract][Full Text] [Related]
31. Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats.
Hine B; Torrelio M; Gershon S
Res Commun Chem Pathol Pharmacol; 1975 Sep; 12(1):185-8. PubMed ID: 1237925
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats.
Cha YM; Jones KH; Kuhn CM; Wilson WA; Swartzwelder HS
Behav Pharmacol; 2007 Sep; 18(5-6):563-9. PubMed ID: 17762524
[TBL] [Abstract][Full Text] [Related]
33. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways.
Verhoeckx KC; Korthout HA; van Meeteren-Kreikamp AP; Ehlert KA; Wang M; van der Greef J; Rodenburg RJ; Witkamp RF
Int Immunopharmacol; 2006 Apr; 6(4):656-65. PubMed ID: 16504929
[TBL] [Abstract][Full Text] [Related]
34. Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids.
Papahatjis DP; Nahmias VR; Andreou T; Fan P; Makriyannis A
Bioorg Med Chem Lett; 2006 Mar; 16(6):1616-20. PubMed ID: 16387492
[TBL] [Abstract][Full Text] [Related]
35. Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: fluorescence studies.
Hillard CJ; Harris RA; Bloom AS
J Pharmacol Exp Ther; 1985 Mar; 232(3):579-88. PubMed ID: 2983062
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi ES; Green MR; Martin BR
J Pharmacol Exp Ther; 1990 Jun; 253(3):1002-9. PubMed ID: 2162942
[TBL] [Abstract][Full Text] [Related]
37. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects.
Rubino T; Forlani G; Viganò D; Zippel R; Parolaro D
J Neurochem; 2005 May; 93(4):984-91. PubMed ID: 15857401
[TBL] [Abstract][Full Text] [Related]
38. Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.
Lu T; Newton C; Perkins I; Friedman H; Klein TW
Eur J Pharmacol; 2006 Feb; 532(1-2):170-7. PubMed ID: 16443217
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
DeLong GT; Wolf CE; Poklis A; Lichtman AH
Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
[TBL] [Abstract][Full Text] [Related]
40. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.
Taffe MA; Creehan KM; Vandewater SA
Br J Pharmacol; 2015 Apr; 172(7):1783-91. PubMed ID: 25425111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
